In this paper PSA and Ki67 immunoreactivity was analyzed as surrogate markers for tumor cell differentiation and proliferation, respectively, and combined to differentiate prostate cancer patients managed by watchful waiting into subgroups with different prognosis and, furthermore, with different biological characteristics with therapeutic implications. This evidence concerns the gene MKI67 and prostate carcinoma.